David M Spencer
Overview
Explore the profile of David M Spencer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
3180
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang X, Cabrera F, Sharp K, Spencer D, Foster A, Bayle J
Mol Ther
. 2021 Feb;
29(2):718-733.
PMID: 33554868
Allogeneic, off-the-shelf (OTS) chimeric antigen receptor (CAR) cell therapies have the potential to reduce manufacturing costs and variability while providing broader accessibility to cancer patients and those with other diseases....
2.
Wang X, Jasinski D, Medina J, Spencer D, Foster A, Bayle J
Blood Adv
. 2020 May;
4(9):1950-1964.
PMID: 32384544
Natural killer (NK) cells expressing chimeric antigen receptors (CARs) are a promising anticancer immunotherapy, leveraging both innate NK cell antitumor activity and target-specific cytotoxicity. Inducible MyD88/CD40 (iMC) is a potent,...
3.
Collinson-Pautz M, Chang W, Lu A, Khalil M, Crisostomo J, Lin P, et al.
Leukemia
. 2019 Mar;
33(9):2195-2207.
PMID: 30816327
Successful adoptive chimeric antigen receptor (CAR) T-cell therapies against hematological malignancies require CAR-T expansion and durable persistence following infusion. Balancing increased CAR-T potency with safety, including severe cytokine-release syndrome (sCRS)...
4.
Duong M, Collinson-Pautz M, Morschl E, Lu A, Szymanski S, Zhang M, et al.
Mol Ther Oncolytics
. 2019 Feb;
12:124-137.
PMID: 30740516
Use of chimeric antigen receptors (CARs) as the basis of targeted adoptive T cell therapies has enabled dramatic efficacy against multiple hematopoietic malignancies, but potency against bulky and solid tumors...
5.
Westera L, Van Viegen T, Jeyarajah J, Azad A, Bilsborough J, van den Brink G, et al.
Clin Transl Gastroenterol
. 2017 Nov;
8(11):e126.
PMID: 29095427
Objectives: Flow cytometry (FC) aids in characterization of cellular and molecular factors involved in pathologic immune responses. Although FC has potential to facilitate early drug development in inflammatory bowel disease,...
6.
Mata M, Gerken C, Nguyen P, Krenciute G, Spencer D, Gottschalk S
Cancer Discov
. 2017 Aug;
7(11):1306-1319.
PMID: 28801306
Adoptive immunotherapy with T cells expressing chimeric antigen receptors (CAR) has had limited success for solid tumors in early-phase clinical studies. We reasoned that introducing into CAR T cells an...
7.
Foster A, Mahendravada A, Shinners N, Chang W, Crisostomo J, Lu A, et al.
Mol Ther
. 2017 Jul;
25(9):2176-2188.
PMID: 28697888
Anti-tumor efficacy of T cells engineered to express chimeric antigen receptors (CARs) is dependent on their specificity, survival, and in vivo expansion following adoptive transfer. Toll-like receptor (TLR) and CD40...
8.
Sonpavde G, McMannis J, Bai Y, Seethammagari M, Bull J, Hawkins V, et al.
Cancer Immunol Immunother
. 2017 Jun;
66(10):1345-1357.
PMID: 28608115
This phase I trial reports the safety and activity of BPX101, a second-generation antigen-targeted autologous antigen presenting cell (APC) vaccine in men with metastatic castration-resistant prostate cancer (mCRPC). To manufacture...
9.
Ono N, Murakami K, Chan O, Hall H, Elford A, Yen P, et al.
PLoS One
. 2017 Mar;
12(3):e0173176.
PMID: 28257518
Although the role of T cells in autoimmunity has been explored for many years, the mechanisms leading to the initial priming of an autoimmune T cell response remain enigmatic. The...
10.
Collinson-Pautz M, Slawin K, Levitt J, Spencer D
PLoS One
. 2016 Oct;
11(10):e0164547.
PMID: 27741278
Therapeutic DNA-based vaccines aim to prime an adaptive host immune response against tumor-associated antigens, eliminating cancer cells primarily through CD8+ cytotoxic T cell-mediated destruction. To be optimally effective, immunological adjuvants...